Strategist-Frontline is set to begin, as the company reports first-line velzatinib data at ASCO.
ApexOnco Front Page
Recent articles
First global data, from Rosetta Lung-02 in first-line NSCLC, tell a familiar story.
Golcadomide and iberdomide are set to feature at EHA.
A Libtayo combo fails to beat Keytruda in first-line melanoma.
Talvey looks good with Darzalex in the second line, while Pomalyst’s role is less clear.
Rival BTK degraders face off in CLL patients naive to BTK inhibition.
The company abandons lorigerlimab in ovarian cancer, and lowers its dose elsewhere.
The Volga muscle-invasive bladder cancer study might have matched Keynote-905.
